NCT03333746View on ClinicalTrials.gov

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

August 13, 2018

Study Completion Date

November 16, 2018

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

American Cancer Society, Inc.

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Yvonne Efebera

OTHER

NCT03333746 - Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter